April 2 (UPI) --Heart disease experts are hailing the results of a clinical trial that showed a strongly positive performance by Eli Lilly's drug lepodisiran, which inhibits the body's production ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

Eli Lilly has recently announced several developments, including positive Phase 2 results for their siRNA therapy lepodisiran and the expansion of their digital healthcare platform, LillyDirect ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can increase the risk of heart attacks and strokes.

Until now. Last week, Eli Lilly and Company announced results of a Phase 2 trial that demonstrated its drug, Lepodisiran, significantly reduced “the production of lipoprotein(a) levels by an average ...

CHICAGO — The remarkable and sustained reductions in lipoprotein(a) ( Lp[a]) achieved with lepodisiran (Eli Lilly) , a novel small-interfering (si)RNA molecule, in a phase 2 trial might signal a ...

In the race to combat dangerous cholesterol levels, Eli Lilly's approach offers a particularly attractive proposition: a single injection of Lepodisiran remains effective for six months.